A Study of KRN23 in Subjects With X-linked Hypophosphatemic Rickets/Osteomalacia
NCT02181764 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15
Last updated 2017-03-03
Summary
The objective of this study is to assess the safety and tolerability of KRN23 after a single subcutaneous (SC) administration in subjects with X-linked hypophosphatemic rickets/osteomalacia (XLH) in Japan or Korea.
Conditions
- X-linked Hypophosphatemic Rickets/Osteomalacia
Interventions
- DRUG
-
KRN23
Single SC administration on day 1: 0.3, 0.6 and 1.0 mg/kg
Sponsors & Collaborators
-
Kyowa Kirin Co., Ltd.
lead INDUSTRY
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2014-07-31
- Primary Completion
- 2015-06-30
- Completion
- 2015-06-30
Countries
- Japan
- South Korea
Study Locations
More Related Trials
-
Clinical Evaluation of Patients With X-linked Retinoschisis
NCT02331173 ·Status: COMPLETED
-
A Safety and Efficacy Study of GTX-102 in Subjects With Deletion- or Nondeletion-type Angelman Syndrome (AS)
NCT07157254 ·Status: RECRUITING ·Phase: PHASE2
-
Long-term Extension of GTX-102 in Angelman Syndrome
NCT06415344 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE3
-
Safety and Tolerability of Subretinally Injected OPGx-BEST1 in Patients With Best Vitelliform Macular Dystrophy (BVMD) or Autosomal-Recessive Bestrophinopathy (ARB)
NCT07185256 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Burosumab in Patients Less Than 1 Year of Age
NCT04188964 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of RO4917523 in Pediatric Patients With Fragile X Syndrome
NCT01750957 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of RO4917523 in Patients With Fragile X Syndrome
NCT01517698 ·Status: COMPLETED ·Phase: PHASE2
-
Clinical Trial in 22q13 Deletion Syndrome(Phelan-McDermid Syndrome)
NCT01525901 ·Status: COMPLETED ·Phase: PHASE2
-
Long-Term Extension of Previous rAvPAL-PEG Protocols in Subjects With PKU (PAL-003)
NCT00924703 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Assess the Safety and Pharmacokinetics of Single Ascending Subcutaneous and Intravenous Doses of DS-2325a in Healthy Subjects
NCT05388903 ·Status: COMPLETED ·Phase: PHASE1
-
Examining the Effect of Burosumab on Muscle Function
NCT04146935 ·Status: COMPLETED ·Phase: PHASE4
-
Safety and Efficacy Study of LX103 Treatment of X-Linked Retinoschisis (XLRS)
NCT05814952 ·Status: RECRUITING ·Phase: NA
-
A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation
NCT06789913 ·Status: RECRUITING ·Phase: PHASE2
-
Efficacy and Safety of Low-Dose Cytarabine Combined With Thalidomide in Adult Patients With Untreated LCH
NCT07187193 ·Status: RECRUITING ·Phase: PHASE2
-
Study to Evaluate the Safety and Efficacy of Pegvaliase in Adolescents (Ages 12-17) With Phenylketonuria
NCT05270837 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Safety and Tolerability Study of rAvPAL-PEG to Treat Phenylketonuria
NCT00634660 ·Status: COMPLETED ·Phase: PHASE1
-
A Study With RO4917523 in Patients With Fragile X Syndrome
NCT01015430 ·Status: COMPLETED ·Phase: PHASE2
-
Assessing Long Term Safety and Tolerability of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A
NCT03023540 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Safety and Efficacy of rAAV-hRS1 in Patients With X-linked Retinoschisis (XLRS)
NCT02416622 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Gene Therapy for X-linked Severe Combined Immunodeficiency (SCID-X1)
NCT01175239 ·Status: UNKNOWN ·Phase: NA
-
A Study of the Safety and Tolerability of GTX-102 in Children With Angelman Syndrome
NCT04259281 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study to Evaluate Subcutaneously Administered rAvPAL-PEG in Patients With Phenylketonuria for 24 Weeks
NCT01560286 ·Status: COMPLETED ·Phase: PHASE2
-
An Open-Label Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of OV101 in Individuals With Angelman Syndrome
NCT03882918 ·Status: TERMINATED ·Phase: PHASE3
-
Open Label Extension to Assess the Long-Term Safety and Tolerability of ZYN002 in Children and Adolescents With FXS
NCT03802799 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE2/PHASE3
-
Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 in Mucopolysaccharidosis III, Type B (MPS IIIB)
NCT02324049 ·Status: COMPLETED ·Phase: PHASE1/PHASE2